×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
JNJ – johnson & johnson (US:NYSE)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
JNJ
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
3/5
04:06 pm
jnj
Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line [Yahoo! Finance]
Low
Report
Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line [Yahoo! Finance]
3/5
03:59 pm
jnj
Johnson & Johnson (JNJ) had its price target raised by JPMorgan Chase & Co. from $225.00 to $250.00. They now have a "neutral" rating on the stock.
Low
Report
Johnson & Johnson (JNJ) had its price target raised by JPMorgan Chase & Co. from $225.00 to $250.00. They now have a "neutral" rating on the stock.
3/5
03:55 pm
jnj
Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line
Low
Report
Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line
3/5
01:29 pm
jnj
The Top High Yield ETFs Every Retiree Should Own [Yahoo! Finance]
Low
Report
The Top High Yield ETFs Every Retiree Should Own [Yahoo! Finance]
3/5
12:27 pm
jnj
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know [Yahoo! Finance]
Low
Report
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know [Yahoo! Finance]
3/5
10:19 am
jnj
Dow Jones opens lower but Nasdaq flat as Broadcom gains [Yahoo! Finance]
Low
Report
Dow Jones opens lower but Nasdaq flat as Broadcom gains [Yahoo! Finance]
3/5
05:28 am
jnj
Microsoft Solutions Partner Aureus Intelligence AI Launches HyperScoper™ - First AI-Powered Instant Estimator for Power Platform and Copilot Projects in the UK [Yahoo! Finance]
Low
Report
Microsoft Solutions Partner Aureus Intelligence AI Launches HyperScoper™ - First AI-Powered Instant Estimator for Power Platform and Copilot Projects in the UK [Yahoo! Finance]
3/4
06:20 pm
jnj
Johnson & Johnson launches website for direct-to-consumer sales [Yahoo! Finance]
Low
Report
Johnson & Johnson launches website for direct-to-consumer sales [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/3
04:26 pm
jnj
Form 4 JOHNSON & JOHNSON For: Feb 27 Filed by: Decker Robert J
Low
Report
Form 4 JOHNSON & JOHNSON For: Feb 27 Filed by: Decker Robert J
2/27
02:35 pm
jnj
Form 144 JOHNSON & JOHNSON Filed by: Decker Robert J
Low
Report
Form 144 JOHNSON & JOHNSON Filed by: Decker Robert J
2/23
05:20 pm
jnj
Form 4 JOHNSON & JOHNSON For: Feb 20 Filed by: Schmid Timothy
Low
Report
Form 4 JOHNSON & JOHNSON For: Feb 20 Filed by: Schmid Timothy
2/20
10:46 am
jnj
Form 144 JOHNSON & JOHNSON Filed by: Schmid Timothy
Low
Report
Form 144 JOHNSON & JOHNSON Filed by: Schmid Timothy
2/18
09:13 pm
jnj
Form 4 JOHNSON & JOHNSON For: Feb 13 Filed by: Swanson James D.
Low
Report
Form 4 JOHNSON & JOHNSON For: Feb 13 Filed by: Swanson James D.
2/18
09:12 pm
jnj
Form 4 JOHNSON & JOHNSON For: Feb 13 Filed by: Mulholland Kristen
Low
Report
Form 4 JOHNSON & JOHNSON For: Feb 13 Filed by: Mulholland Kristen
2/18
09:12 pm
jnj
Form 4 JOHNSON & JOHNSON For: Feb 13 Filed by: Wolk Joseph J
Low
Report
Form 4 JOHNSON & JOHNSON For: Feb 13 Filed by: Wolk Joseph J
2/18
09:12 pm
jnj
Form 4 JOHNSON & JOHNSON For: Feb 13 Filed by: Taubert Jennifer L
Low
Report
Form 4 JOHNSON & JOHNSON For: Feb 13 Filed by: Taubert Jennifer L
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/27
Form DEFA14A JOHNSON & JOHNSON
8.1%
3/12 Paul Harris' Top Picks: March 12, 2020 [Business News Network (BNN) Energy & Resources (Canada)] 7.5%
4/7 Is JNJ Stock A Buy On CEO's Bullish Call For Coronavirus Vaccine? [Investor's Business Daily] 4.6%
4/5 Will These 3 Coronavirus Stocks Lead the Market to Recovery? [Yahoo! Finance News] 4.3%
4/13 Stocks slip as market enters new phase, with investors worrying about balance sheets [CNBC] 4.0%
3/2 AODocs Joins AIIM Leadership Council, Showcases Innovative Approach to Information Management at 2020 AIIM Conference 3.9%
3/4 Johnson & Johnson ordered to pay $1.7 million to three Australian women in pelvic mesh class action [Reuters] 3.8%
3/18 Is This 1 Healthcare Stock Coronavirus-Proof? [The Motley Fool] 3.8%
3/24 What Technology And Manufacturing Can Do To Help Against COVID-19 [Forbes] 3.6%
4/1 5 of the Best Stocks to Buy for April [Yahoo! Finance News] 3.3%
3/12 Paul Harris' Top Picks: March 12, 2020 [Business News Network (BNN) Energy & Resources (Canada)] 7.5%
4/7 Is JNJ Stock A Buy On CEO's Bullish Call For Coronavirus Vaccine? [Investor's Business Daily] 4.6%
4/5 Will These 3 Coronavirus Stocks Lead the Market to Recovery? [Yahoo! Finance News] 4.3%
4/13 Stocks slip as market enters new phase, with investors worrying about balance sheets [CNBC] 4.0%
3/2 AODocs Joins AIIM Leadership Council, Showcases Innovative Approach to Information Management at 2020 AIIM Conference 3.9%
3/4 Johnson & Johnson ordered to pay $1.7 million to three Australian women in pelvic mesh class action [Reuters] 3.8%
3/18 Is This 1 Healthcare Stock Coronavirus-Proof? [The Motley Fool] 3.8%
3/24 What Technology And Manufacturing Can Do To Help Against COVID-19 [Forbes] 3.6%
4/1 5 of the Best Stocks to Buy for April [Yahoo! Finance News] 3.3%
TOP News Decliners
3/21
Johnson and Johnson: A Safe Haven in Recession [The Motley Fool]
-7.3%
3/20 Is Johnson & Johnson (NYSE:JNJ) Trading At A 35% Discount? [Yahoo! Finance News] -6.9%
3/10 J&J MET antibody nabs accelerated review status for certain lung cancer patients [Seeking Alpha] -6.8%
3/18 J&J files U.S. application for MS med ponesimod [Seeking Alpha] -6.6%
10/18 Wolves In Sheep’s Clothing: We Can’t Trust Businesses To Do Right By Americans Now [Forbes] -6.4%
5/28 Oklahoma taking on Johnson & Johnson in historic trial [MSNBC.com] -6.1%
3/13 Americans rush to stock up on essentials as coronavirus spreads [Reuters] -5.5%
3/11 Desperate to exit, a $10B price tag for Magic Leap is crazy [TechCrunch Blog] -4.9%
7/12 Johnson & Johnson (NYSE: JNJ) is now covered by analysts at Credit Suisse Group AG. They set an "outperform" rating and a $156.00 price target on the stock. -4.5%
3/6 Eyecare industry leaders sign Proclamation to focus on key issues facing the future of optometry -3.8%
3/20 Is Johnson & Johnson (NYSE:JNJ) Trading At A 35% Discount? [Yahoo! Finance News] -6.9%
3/10 J&J MET antibody nabs accelerated review status for certain lung cancer patients [Seeking Alpha] -6.8%
3/18 J&J files U.S. application for MS med ponesimod [Seeking Alpha] -6.6%
10/18 Wolves In Sheep’s Clothing: We Can’t Trust Businesses To Do Right By Americans Now [Forbes] -6.4%
5/28 Oklahoma taking on Johnson & Johnson in historic trial [MSNBC.com] -6.1%
3/13 Americans rush to stock up on essentials as coronavirus spreads [Reuters] -5.5%
3/11 Desperate to exit, a $10B price tag for Magic Leap is crazy [TechCrunch Blog] -4.9%
7/12 Johnson & Johnson (NYSE: JNJ) is now covered by analysts at Credit Suisse Group AG. They set an "outperform" rating and a $156.00 price target on the stock. -4.5%
3/6 Eyecare industry leaders sign Proclamation to focus on key issues facing the future of optometry -3.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: